表紙
市場調査レポート

世界の個別化医療市場の分析

Personalized Medicine Market Analysis

発行 RNCOS E-Services Pvt. Ltd. 商品コード 228193
出版日 ページ情報 英文 90 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界の個別化医療市場の分析 Personalized Medicine Market Analysis
出版日: 2013年05月13日 ページ情報: 英文 90 Pages
概要

ヒトDNAの解析が進むにつれ、世界の医療産業に「個別化医療」と呼ばれる分野が新たに誕生し、急速に成長しています。例えば、米国では2012〜2017年に、年平均で9.5%もの成長を遂げると予想されています。がんなどの疾病の早期検知・効率的治療の必要性が、個別化医療の主な促進要因となっています。

当レポートでは、米国およびその他の国々での個別化医療産業について調査し、技術的特徴や全体的な市場構造(市場促進・抑制要因)、各国市場の動向、市場競争状態、関連産業への影響、主要企業の概要といった内容を盛り込んで、以下の構成でお届けします。

第1章 アナリストの見解

第2章 分析手法

第3章 個別化医療市場の概説

第4章 個別化医療市場

  • 治療
    • がん
    • 心血管疾患
    • 神経疾患
  • 診断

第5章 市場参加企業

  • 医薬品企業
  • 診断薬企業
  • 技術プロバイダー企業
  • 医療機関
  • 保険企業

第6章 主要国の市場

  • 米国
  • 欧州
  • 新興国市場
    • 日本
    • 中国
    • インド

第7章 市場促進・抑制要因

  • 市場促進要因
    • がん治療における個別化医療への関心増大
    • 薬理ゲノミクス・薬理遺伝学の大幅な進展
    • 医薬品副作用(ADR)防止の個人化
    • 医療費の抑制
  • 市場抑制要因
    • 医療費還付
    • プライバシー・機密保持・患者の権利

第8章 規制環境

第9章 競争環境

  • 医薬品・バイオテクノロジー企業
    • Abbott Laboratories
    • Genzyme Corporation
    • Novartis AG
    • Bristol-Myers Squibb Company
  • IT・インフォマティクス企業
    • IBM
    • Oracle Health Sciences
    • XIFIN, Inc.
    • CTIS, Inc.
  • 診断薬企業
    • Siemens
    • Roche
    • Rosetta Genomics Ltd.
    • QIAGEN N.V.
    • Gen-Probe Incorporated
    • Dako Denmark A/S
    • BioMerieux SA
  • 分析ツール企業
    • Affymetrix, Inc.
    • DNA Genotek
    • Illumina, Inc.
    • Life Technologies Corporation
    • Pacific Biosciences

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Advancements in the field of genomics have created ample opportunities for personalized medicines to emerge in the healthcare industry. Personalized medicine represents an interface of therapeutics and diagnostics. It involves the tailoring of treatments as per individuals. The growing research applications and identification of molecular markers towards disease predisposition and progression have led to the growth of personalized medicine. Industry players have also rapidly adopted this field and are progressing towards achieving higher goals in the same.

According to our new research report, “Personalized Medicine Market Analysis”, the U.S. represents the brightest market for personalized medicine and is anticipated to grow at a CAGR of around 9.5% during 2012-2017. The need for rapid detection of diseases, especially cancer,and their more efficient treatments are primarily driving this market.

Besides USA, countries like the U.K., France, Germany, India, China, and Japan have also been trying to pioneer personalized medicine with the help of advanced technologies. A lot of investment has been undergoing for research and development to develop biomarkers and personalized healthcare solutions in order to improve the medical outcomes. Our report provides a prudent analysis at the country level, elucidating the level of personalized medicine penetration, recent industry developments and the future growth prospects.

Companies are actively involved in the development of advanced technological tools and diagnostic equipments that help in promoting personalized medicine. Strategic alliances and consolidation has also become a common trend towards greater market presence. Academic and private research institutions as well as small biotech and major pharmaceutical companies are increasingly looking for alternative ways to strengthen their pipelines. The report highlights the various strategies being adopted by market players and research institutes to promote growth in this field.

The report also covers the industry positioning in terms of the major therapeutic areas. The study also provides an insight into the segment-wise competitive landscape, which includes the profiles of Pharmaceutical/Biotech, Diagnostic, IT/Informatics, and Research Tool companies across the globe. Through the report, companies planning to venture into the personalized medicine sector will also have an in-depth understanding of the industry dynamics.

Table of Contents

1. Analyst View

2. Research Methodology

3. Personalized Medicine Market: An Introduction

4. Personalized Medicine Market

  • 4.1. Therapeutics
    • 4.1.1. Cancer
    • 4.1.2. Cardiovascular Diseases
    • 4.1.3. Neurological Disorders
  • 4.2. Diagnostics

5. Market Participants

  • 5.1. Pharmaceutical Companies
  • 5.2. Diagnostic Companies
  • 5.3. Technology Providers
  • 5.4. Healthcare Providers
  • 5.5. Insurance Companies

6. Key Geographical Markets

  • 6.1. US
  • 6.2. Europe
  • 6.3. Emerging Markets
    • 6.3.1. Japan
    • 6.3.2. China
    • 6.3.3. India

7. Market Drivers and Restraints

  • 7.1. Drivers
    • 7.1.1. Increasing Focus of Personalized Medicine in Cancer
    • 7.1.2. Robust Advancements in Pharmacogenomics and Pharmacogenetics
    • 7.1.3. Personalization for Prevention of ADR's
    • 7.1.4. Healthcare Costs Savings
  • 7.2. Restraints
    • 7.2.1. Reimbursement
    • 7.2.2. Privacy, Confidentiality and Patients' Rights

8. Regulatory Environment

9. Competitive Landscape

  • 9.1. Pharma/Biotech Companies
    • 9.1.1. Abbott Laboratories
    • 9.1.2. Genzyme Corporation
    • 9.1.3. Novartis AG
    • 9.1.4. Bristol-Myers Squibb Company
  • 9.2. IT/Informatics Companies
    • 9.2.1. IBM
    • 9.2.2. Oracle Health Sciences
    • 9.2.3. XIFIN, Inc.
    • 9.2.4. CTIS, Inc.
  • 9.3. Diagnostic Companies
    • 9.3.1. Siemens
    • 9.3.2. Roche
    • 9.3.3. Rosetta Genomics Ltd.
    • 9.3.4. QIAGEN N.V.
    • 9.3.5. Gen-Probe Incorporated
    • 9.3.6. Dako Denmark A/S
    • 9.3.7. BioMérieux SA
  • 9.4. Research Tool Companies
    • 9.4.1. Affymetrix, Inc.
    • 9.4.2. DNA Genotek
    • 9.4.3. Illumina, Inc.
    • 9.4.4. Life Technologies Corporation
    • 9.4.5. Pacific Biosciences

List of Figures:

  • Figure 6-1: US - Personalized Medicine Market (Billion US$), 2012-2017
  • Figure 6-2: US - Personalized Medicine Market by Segment (%), 2012

List of Tables:

  • Table 4-1: Personalized Medicine for Cancer by Therapy (2011)
  • Table 4-2: Personalized Medicine for Cardiovascular Diseases by Therapy (2011)
  • Table 4-3: Personalized Medicine for Neurological Disorders by Therapy (2011)
Back to Top